Robust inference for causal mediation analysis of recurrent event data

被引:0
作者
Chen, Yan-Lin [1 ]
Chen, Yan-Hong [2 ]
Su, Pei-Fang [3 ]
Ou, Huang-Tz [4 ]
Tai, An-Shun [3 ]
机构
[1] Natl Yang Ming Chiao Tung Univ, Inst Stat, Hsinchu, Taiwan
[2] Acad Sinica, Inst Stat Sci, Taipei, Taiwan
[3] Natl Cheng Kung Univ, Dept Stat, Tainan, Taiwan
[4] Natl Cheng Kung Univ, Coll Med, Dept Pharm, Tainan, Taiwan
关键词
causal inference; inverse probability weighting; mediation analysis; recurrent events; robust inference; triply robust estimation; CARDIOVASCULAR-DISEASE; KIDNEY-DISEASE; INHIBITORS; REGRESSION; MODEL;
D O I
10.1002/sim.10118
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recurrent events, including cardiovascular events, are commonly observed in biomedical studies. Understanding the effects of various treatments on recurrent events and investigating the underlying mediation mechanisms by which treatments may reduce the frequency of recurrent events are crucial tasks for researchers. Although causal inference methods for recurrent event data have been proposed, they cannot be used to assess mediation. This study proposed a novel methodology of causal mediation analysis that accommodates recurrent outcomes of interest in a given individual. A formal definition of causal estimands (direct and indirect effects) within a counterfactual framework is given, and empirical expressions for these effects are identified. To estimate these effects, a semiparametric estimator with triple robustness against model misspecification was developed. The proposed methodology was demonstrated in a real-world application. The method was applied to measure the effects of two diabetes drugs on the recurrence of cardiovascular disease and to examine the mediating role of kidney function in this process.
引用
收藏
页码:3020 / 3035
页数:16
相关论文
共 44 条
  • [1] Andersen P.K., 2012, Statistical Models Based on Counting Processes
  • [2] COX REGRESSION-MODEL FOR COUNTING-PROCESSES - A LARGE SAMPLE STUDY
    ANDERSEN, PK
    GILL, RD
    [J]. ANNALS OF STATISTICS, 1982, 10 (04) : 1100 - 1120
  • [3] [Anonymous], Authorisation of Medicines
  • [4] Avin C., IDENTIFIABILITY PATH
  • [5] Cook RJ, 2007, STAT BIOL HEALTH, P1, DOI 10.1007/978-0-387-69810-6
  • [6] Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
    Cornel, Jan H.
    Bakris, George L.
    Stevens, Susanna R.
    Alvarsson, Michael
    Bax, Willem A.
    Chuang, Lee-Ming
    Engel, Samuel S.
    Lopes, Renato D.
    McGuire, Darren K.
    Riefflin, Axel
    Rodbard, Helena Wachslicht
    Sinay, Isaac
    Tankova, Tsvetalina
    Wainstein, Julio
    Peterson, Eric D.
    Holman, Rury R.
    [J]. DIABETES CARE, 2016, 39 (12) : 2304 - 2310
  • [7] Davies MJ, 2018, DIABETOLOGIA, V61, P2461, DOI [10.2337/dci18-0033, 10.1007/s00125-018-4729-5]
  • [8] Relationship between classic vascular risk factors and cumulative recurrent cardiovascular event burden in patients with clinically manifest vascular disease: results from the UCC-SMART prospective cohort study
    de Vries, Tamar Irene
    Westerink, Jan
    Bots, Michiel L.
    Asselbergs, Folkert W.
    Smulders, Yvo M.
    Visseren, Frank L. J.
    [J]. BMJ OPEN, 2021, 11 (03):
  • [9] Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
    Drucker, DJ
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2003, 12 (01) : 87 - 100
  • [10] ElSayed NA, 2023, DIABETES CARE, V46, pS191, DOI 10.2337/dc23-S011